Sale

Sarcoidosis Market

Sarcoidosis Market Size, Share, Growth, Trends, Forecast: By Diagnostic Method: Imaging Technique, Biopsy, Blood Tests; By Treatment Type: Corticosteroids, Immunosuppressive Agents, Biologics, Anti-malarial Drugs; By Route of Administration; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Sarcoidosis Market Outlook

The sarcoidosis market size is expected to grow at a CAGR of 3.8% during the forecast period of 2024-2032, driven by the extensive research activities aimed at finding effective therapeutic solutions and the growing demand for personalized medicines across the 8 major markets. 

 

Sarcoidosis Market Overview

Sarcoidosis is an inflammatory disease characterized by the formation of tiny granulomas or lumps. It predominantly affects the lungs or lymph nodes, resulting in inflammation and possible organ damage. Depending on the region, the annual incidence of the disease ranges from 1 to 15 per 100,000 individuals, with higher rates found in North America (5-10/100,000) and the highest in Northern Europe (11-15/100,000).  The rising burden of sarcoidosis is projected to drive the sarcoidosis market growth in the forecast period.

 

Factors such as increased funding from various sectors and extensive research initiatives are positively impacting the market landscape. In December 2023, the Foundation for Sarcoidosis Research (FSR) awarded a grant of USD 100,000 to support two United States-based research projects involved in understanding the disease and diagnosis of cardiac sarcoidosis, with each project receiving USD 50,000. The funding is expected to encourage research in diagnosis techniques, prognosis, and treatment alternatives for cardiac sarcoidosis. Till now, FSR has awarded USD 6.5 million for sarcoidosis research via its grant program.  Such fundings provide essential support to accommodate the growing sarcoidosis market demand and contribute to the market growth significantly.

 

The market is also driven by the surge in drug approvals by regulatory health agencies such as the United States Food and Drug Administration (FDA) to meet the clinical needs of patients suffering from sarcoidosis. Moreover, the rising patient awareness and the advancement in the healthcare sector is poised to fuel market growth.

 

Sarcoidosis Market Trends

Key Trend Impact
Advancements in Diagnostic Techniques Improved diagnostic techniques, including advanced imaging technologies and molecular diagnostic tools, are increasing the accuracy and efficiency of sarcoidosis diagnosis.
Emergence of Targeted Therapies The development of targeted therapies aimed at specific pathways and mechanisms involved in sarcoidosis is resulting in more effective and less toxic treatment options compared to traditional therapies.
Increased Focus on Personalized Medicine Personalized medicine approaches are driving demand in the sarcoidosis market, with research aimed at identifying genetic markers and other biomarkers that can predict disease progression and treatment response. 
Increased Clinical Trials There is a notable increase in the number of clinical trials for sarcoidosis, focusing on new therapeutic agents. This expansion is driven by the unmet need for more effective and tolerable treatments.

 

Sarcoidosis Market Segmentation

Market Breakup by Diagnostic Method

  • Imaging Techniques
    • Chest X-rays
    • CT scans
    • MRI scans
  • Biopsy
    • Bronchoscopy
    • Skin Biopsy
    • Lymph Node Biopsy
  • Blood Tests
    • Angiotensin-converting enzyme (ACE) levels
    • Serum Calcium Levels
    • Liver Function Tests

The market segmentation by diagnostic methods includes imaging techniques, biopsy, and blood tests. Imaging techniques comprise chest X-rays, CT scans, and MRI scans to visualize affected areas. Biopsy procedures such as bronchoscopy, skin biopsy, and lymph node biopsy provide tissue samples for examination. Blood tests measure angiotensin-converting enzyme (ACE) levels, serum calcium levels, and liver function for a comprehensive assessment.

 

Market Breakup by Treatment Type

  • Corticosteroids
    • Oral Corticosteroids
    • Inhaled Corticosteroids
  • Immunosuppressive Agents
    • Methotrexate
    • Azathioprine
    • Mycophenolate Mofetil
  • Biologics
    • Tumor Necrosis Factor (TNF) Inhibitors
    • Interleukin Inhibitors
  • Anti-malarial Drugs
    • Hydroxychloroquine

By treatment type, the market is divided into various options: corticosteroids, including oral and inhaled forms, to manage inflammation, immunosuppressive agents like methotrexate, azathioprine, and mycophenolate mofetil, biologics such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors and anti-malarial drugs like hydroxychloroquine offer additional therapeutic interventions.

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

 

The sarcoidosis market share is segmented by route of administration into oral, and parenteral, among others. Oral medications are taken by mouth, while parenteral options involve injection or infusion.

 

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

 

End users of the market are hospitals, specialty clinics, homecare, and others. This market segment represents treatment and care settings for the sarcoidosis patients.

 

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

 

Based on distribution channels, the sarcoidosis market segmentation is divided into hospital pharmacy, retail pharmacy, online pharmacy, and others.

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • China

 

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China. North America leads the market share supported by the rising investments from the key market players to address the unmet needs of sarcoidosis patients. In addition, the advanced healthcare infrastructure and access to various treatment options are also driving the market demand.

 

Sarcoidosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Merck & Co., Inc.
  • Fresenius Kabi USA
  • Zydus Pharmaceuticals, Inc.
  • Sanofi-aventis U.S. LLC
  • Hoffmann-La Roche Ltd
  • Teva Pharmaceuticals USA, Inc.
  • Sandoz International GmbH
  • Relief Therapeutics
  • Pfizer Inc.
  • AbbVie Inc.
  • Mallinckrodt
  • Amneal Pharmaceuticals LLC.
  • Mylan N.V.
  • Hikma Pharmaceuticals PLC

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Diagnostic Method
  • Treatment Type
  • Route of Administration
  • End User
  • Distribution Channel
  • Region
Breakup by Diagnostic Method
  • Imaging Technique
  • Biopsy
  • Blood Tests
Breakup by Treatment Type
  • Corticosteroids
  • Immunosuppressive Agents
  • Biologics
  • Anti-malarial Drugs
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by End User
  • Hospitals
  • Specialty Clinics 
  • Homecare
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy 
  • Retail Pharmacy
  • Online Pharmacy
  • Other
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • China
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Merck & Co., Inc.
  • Fresenius Kabi USA
  • Zydus Pharmaceuticals, Inc.
  • Sanofi-aventis U.S. LLC
  • Hoffmann-La Roche Ltd
  • Teva Pharmaceuticals USA, INC
  • Sandoz International GmbH
  • Relief Therapeutics
  • Pfizer Inc.
  • AbbVie Inc.
  • Mallinckrodt
  • Amneal Pharmaceuticals LLC.
  • Mylan N.V.
  • Hikma Pharmaceuticals PLC

 

Key Queries Solved in the Sarcoidosis Market Report

  • How will the market dynamics evolve in the sarcoidosis market in the coming years?
  • What are the primary drivers propelling the expansion of the market?
  • What are the main challenges impeding the growth of the market?
  • What treatment options are currently accessible for sarcoidosis, and which treatment type dominates the market segment?
  • What emerging trends and advancements are influencing the diagnosis and treatment of sarcoidosis?
  • How does the regulatory framework impact market dynamics?
  • How does the prevalence of sarcoidosis influence market growth?
  • Which diagnostic method is expected to contribute significantly to the sarcoidosis market value?
  • How will the ongoing clinical trials impact the market value during the forecast period? 
  • What are the factors driving regional disparities in major depressive disorder treatment and outcomes?
  • How are technological advancements in diagnostics impacting the management of sarcoidosis?
  • What regional factors are influencing the growth trajectory of the sarcoidosis market?
  • What strategies are market players employing in the sarcoidosis market?
  • What potential opportunities for innovation exist in the sarcoidosis market?

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Sarcoidosis Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Sarcoidosis Epidemiology Analysis – 8 Major Markets
    5.1    8MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Sarcoidosis Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Sarcoidosis Epidemiology Forecast (2017-2032)
        5.3.1    Germany Sarcoidosis Epidemiology Forecast (2017-2032)
        5.3.2    France Sarcoidosis Epidemiology Forecast (2017-2032)
        5.3.3    Italy Sarcoidosis Epidemiology Forecast (2017-2032)
        5.3.4    Spain Sarcoidosis Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Sarcoidosis Epidemiology Forecast (2017-2032)
    5.4    Japan Sarcoidosis Epidemiology Forecast (2017-2032) 
    5.5    China Sarcoidosis Epidemiology Forecast (2017-2032)
6    Sarcoidosis Market  Overview – 8 Major Markets 
    6.1    Sarcoidosis Market Historical Value (2017-2023) 
    6.2    Sarcoidosis Market Forecast Value (2024-2032)
7    Sarcoidosis Market Landscape – 8 Major Markets 
    7.1    Sarcoidosis: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Sarcoidosis: Product Landscape
        7.2.1    Analysis by Diagnostic Method
        7.2.2    Analysis by Treatment Type
        7.2.3    Analysis by Route of Administration 
8    Sarcoidosis Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Sarcoidosis  Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
        10.2.1    Strengths
        10.2.2    Weaknesses
        10.2.3    Opportunities
        10.2.4    Threats
    10.3    Porter’s Five Forces Model
        10.3.1    Bargaining Power of Suppliers
        10.3.2    Bargaining Power of Buyers
        10.3.3    Threat of New Entrants
        10.3.4    Threat of Substitutes
        10.3.5    Degree of Rivalry
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Sarcoidosis Market Segmentation-8 Major Markets 
    11.1    Sarcoidosis Market by Diagnostic Method
        11.1.1    Market Overview
        11.1.2    Imaging Technique
            11.1.2.1    Chest X-rays
            11.1.2.2    CT Scans
            11.1.2.3    MRI Scans
        11.1.3    Biopsy
            11.1.3.1    Bronchoscopy
            11.1.3.2    Skin Biopsy
            11.1.3.3    Lymph Node Biopsy
        11.1.4    Blood Tests
            11.1.4.1    Angiotensin-converting enzyme (ACE) levels
            11.1.4.2    Serum calcium levels
            11.1.4.3    Liver function tests
    11.2    Sarcoidosis Market by Treatment Type 
        11.2.1    Market Overview
        11.2.2    Corticosteroids
            11.2.2.1    Oral Corticosteroids
            11.2.2.2    Inhaled Corticosteroids
        11.2.3    Immunosuppressive Agents
            11.2.3.1    Methotrexate
            11.2.3.2    Azathioprine
            11.2.3.3    Mycophenolate mofetil
        11.2.4    Biologics
            11.2.4.1    Tumor Necrosis Factor (TNF) Inhibitors
            11.2.4.2    Interleukin Inhibitors
        11.2.5    Anti-malarial Drugs
            11.2.5.1    Hydroxychloroquine
    11.3    Sarcoidosis Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Parenteral
        11.3.4    Others
    11.4    Sarcoidosis Market by End User
        11.4.1    Market Overview
        11.4.2    Hospitals
        11.4.3    Specialty Clinics 
        11.4.4    Homecare
        11.4.5    Others
    11.5    Sarcoidosis Market by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacy 
        11.5.3    Retail Pharmacy
        11.5.4    Online Pharmacy
        11.5.5    Others
    11.6    Sarcoidosis Market by Region
        11.6.1    Market Overview
        11.6.2    United States
        11.6.3    EU-4 and the United Kingdom
            11.6.3.1    Germany
            11.6.3.2    France
            11.6.3.3    Italy
            11.6.3.4    Spain
            11.6.3.5    United Kingdom
        11.6.4    Japan
        11.6.5    China
12    United States Sarcoidosis Market
    12.1    United States Sarcoidosis Market Historical Value (2017-2023) 
    12.2    United States Sarcoidosis Market Forecast Value (2024-2032)
    12.3    United States Sarcoidosis Market by Treatment Type 
        12.3.1    Market Overview
        12.3.2    Corticosteroids
            12.3.2.1    Oral Corticosteroids
            12.3.2.2    Inhaled Corticosteroids
        12.3.3    Immunosuppressive Agents
            12.3.3.1    Methotrexate
            12.3.3.2    Azathioprine
            12.3.3.3    Mycophenolate mofetil
        12.3.4    Biologics
            12.3.4.1    Tumor Necrosis Factor (TNF) Inhibitors
            12.3.4.2    Interleukin Inhibitors
        12.3.5    Anti-malarial Drugs
            12.3.5.1    Hydroxychloroquine
    12.4    United States Sarcoidosis Market by Route of Administration
        12.4.1    Market Overview
        12.4.2    Oral
        12.4.3    Parenteral
        12.4.4    Others
13    EU-4 and United Kingdom Sarcoidosis Market
    13.1    EU-4 and United Kingdom Sarcoidosis Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom Sarcoidosis Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom Sarcoidosis Market by Treatment Type 
        13.3.1    Market Overview
        13.3.2    Corticosteroids
            13.3.2.1    Oral Corticosteroids
            13.3.2.2    Inhaled Corticosteroids
        13.3.3    Immunosuppressive Agents
            13.3.3.1    Methotrexate
            13.3.3.2    Azathioprine
            13.3.3.3    Mycophenolate mofetil
        13.3.4    Biologics
            13.3.4.1    Tumor Necrosis Factor (TNF) Inhibitors
            13.3.4.2    Interleukin Inhibitors
        13.3.5    Anti-malarial Drugs
            13.3.5.1    Hydroxychloroquine
    13.4    EU-4 and United Kingdom Sarcoidosis Market by Route of Administration
        13.4.1    Market Overview
        13.4.2    Oral
        13.4.3    Parenteral
        13.4.4    Others
14    Japan Sarcoidosis Market
    14.1    Japan Sarcoidosis Market Historical Value (2017-2023) 
    14.2    Japan Sarcoidosis Market Forecast Value (2024-2032)
    14.3    Japan Sarcoidosis Market by Treatment Type 
        14.3.1    Market Overview
        14.3.2    Corticosteroids
            14.3.2.1    Oral Corticosteroids
            14.3.2.2    Inhaled Corticosteroids
        14.3.3    Immunosuppressive Agents
            14.3.3.1    Methotrexate
            14.3.3.2    Azathioprine
            14.3.3.3    Mycophenolate mofetil
        14.3.4    Biologics
            14.3.4.1    Tumor Necrosis Factor (TNF) Inhibitors
            14.3.4.2    Interleukin Inhibitors
        14.3.5    Anti-malarial Drugs
            14.3.5.1    Hydroxychloroquine
    14.4    Japan Sarcoidosis Market by Route of Administration
        14.4.1    Market Overview
        14.4.2    Oral
        14.4.3    Parenteral
        14.4.4    Others
15    China Sarcoidosis Market
    15.1    China Sarcoidosis Market Historical Value (2017-2023) 
    15.2    China Sarcoidosis Market Forecast Value (2024-2032)
    15.3    China Sarcoidosis Market by Treatment Type 
        15.3.1    Market Overview
        15.3.2    Corticosteroids
            15.3.2.1    Oral Corticosteroids
            15.3.2.2    Inhaled Corticosteroids
        15.3.3    Immunosuppressive Agents
            15.3.3.1    Methotrexate
            15.3.3.2    Azathioprine
            15.3.3.3    Mycophenolate mofetil
        15.3.4    Biologics
            15.3.4.1    Tumor Necrosis Factor (TNF) Inhibitors
            15.3.4.2    Interleukin Inhibitors
        15.3.5    Anti-malarial Drugs
            15.3.5.1    Hydroxychloroquine
    15.4    China Sarcoidosis Market by Route of Administration
        15.4.1    Market Overview
        15.4.2    Oral
        15.4.3    Parenteral
        15.4.4    Others
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    Japan PMDA
        16.1.4    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    Merck & Co., Inc.
        22.1.1    Financial Analysis
        22.1.2    Product Portfolio
        22.1.3    Demographic Reach and Achievements
        22.1.4    Mergers and Acquisition
        22.1.5    Certifications
    22.2      Fresenius Kabi USA
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisition
        22.2.5    Certifications
    22.3    Zydus Pharmaceuticals, Inc.
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisition
        22.3.5    Certifications
    22.4    Sanofi-aventis U.S. LLC
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisition
        22.4.5    Certifications
    22.5     Hoffmann-La Roche Ltd
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisition
        22.5.5    Certifications
    22.6    Teva Pharmaceuticals USA, INC
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisition
        22.6.5    Certifications
    22.7     Sandoz International GmbH
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisition
        22.7.5    Certifications
    22.8     Relief Therapeutics
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisition
        22.8.5    Certifications
    22.9    Pfizer Inc.
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisition
        22.9.5    Certifications
    22.10    AbbVie Inc.
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisition
        22.10.5    Certifications
    22.11    Mallinckrodt
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisition
        22.11.5    Certifications
    22.12    Amneal Pharmaceuticals LLC.
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisition
        22.12.5    Certifications
    22.13    Mylan N.V.
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisition
        22.13.5    Certifications
    22.14     Hikma Pharmaceuticals PLC
        22.14.1    Financial Analysis
        22.14.2    Product Portfolio
        22.14.3    Demographic Reach and Achievements
        22.14.4    Mergers and Acquisition
        22.14.5    Certifications
23    Sarcoidosis Treatment - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)

    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

The market is anticipated to grow at a CAGR of 3.8% during the forecast period of 2024-2032, driven by the extensive research activities aimed at finding effective therapeutic solutions and the growing demand for personalized medicines across the 8 major markets.

The market demand is driven by the emergence of targeted therapies and advancement in diagnostic techniques.

One of the significant trends in the market is the increased funding to support sarcoidosis-related research. In December 2023, the Foundation for Sarcoidosis Research (FSR) awarded a grant of USD 100,000 to support two United States-based research projects involved in understanding the disease and diagnosis of cardiac sarcoidosis, with each project receiving USD 50,000.

Based on the treatment type, the market is segmented into corticosteroids, immunosuppressive agents, biologics, and anti-malarial drugs. Corticosteroids are further divided into oral and inhaled forms. Immunosuppressive agents include methotrexate, azathioprine, and mycophenolate mofetil, while biologics include tumor necrosis factor (TNF) inhibitors and interleukin inhibitors. Anti-malarial drugs like hydroxychloroquine are also used as a treatment type.

Diagnostic methods available in the market include imaging techniques, biopsy, and blood tests. 

The sarcoidosis market share is segmented by route of administration into oral, and parenteral, among others.

Major end users of the market are hospitals, specialty clinics, homecare, and others. 

Distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.

The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China.

Key players involved in the market are Merck & Co., Inc., Fresenius Kabi USA, Zydus Pharmaceuticals, Inc., Sanofi-aventis U.S. LLC, Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc., Sandoz International GmbH, Relief Therapeutics, Pfizer Inc., AbbVie Inc., Mallinckrodt, Amneal Pharmaceuticals LLC, Mylan N.V., and Hikma Pharmaceuticals PLC.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER